Bio

Honors & Awards


  • Michael Cuccione Childhood Cancer Foundation Doctoral Studentship, Michael Cuccione Foundation (2016-2017)
  • Child and Family Research Institute Graduate Studentship, BC Children's Hospital Research Institute (2014-2016)
  • Sandy Kyo-Hyun Park Scholarship for Cancer Research, University of British Columbia (2014)
  • University of British Columbia Faculty of Medicine Graduate Achievement Award, University of British Columbia (2014)
  • NSERC Undergraduate Research Award, Natural Sciences and Engineering Research Council of Canada (2011)

Professional Education


  • Bachelor of Science, Simon Fraser University (2012)
  • Doctor of Philosophy, University of British Columbia (2017)

Research & Scholarship

Lab Affiliations


Publications

All Publications


  • IFN-gamma directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life EUROPEAN JOURNAL OF IMMUNOLOGY Fidanza, M., Seif, A. E., Jo, S., Kariminia, A., Rolf, N., Sly, L. M., Grupp, S. A., Reid, G. S. 2017; 47 (5): 892-899

    Abstract

    The early-life immune environment has been implicated as a modulator of acute lymphoblastic leukemia (ALL) development in children, with infection being associated with significant changes in ALL risk. Furthermore, polymorphisms in several cytokine genes, including IL-10 and IFN-γ, are associated with leukemia development. However, the mechanisms and timing of these influences remain unknown. Here, we use the Eμ-ret transgenic mouse model of B-cell precursor ALL to assess the influence of IFN-γ on the early-life burden of leukemia-initiating cells. The absence of IFN-γ activity resulted in greater numbers of leukemia-initiating cells early in life and was associated with accelerated leukemia onset. The leukemia-initiating cells from IFN-γ-knockout mice had reduced suppressor of cytokine signaling (SOCS-1) expression, were significantly more sensitive to IFN-γ, and exhibited more rapid expansion in vivo than their wild-type counterparts. However, sensitivity to this inhibitory pathway was lost in fully transformed IFN-γ-knockout leukemia cells. These results demonstrate that the influence of IFN-γ on ALL progression may not be mediated by selection of nascent transformed cells but rather through a general SOCS-mediated reduction in B-cell precursor proliferation. Thus, while cytokine levels may influence leukemia at multiple points during disease progression, our study indicates a significant early influence of basal, infection-independent cytokine production on leukemogenesis.

    View details for DOI 10.1002/eji.201646806

    View details for Web of Science ID 000401010500014

    View details for PubMedID 28295300

  • Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses LEUKEMIA Fidanza, M., Seif, A. E., Demicco, A., Rolf, N., Jo, S., Yin, B., Li, Y., Barrett, D. M., Duque-Afonso, J., Cleary, M. L., Bassing, C. H., Grupp, S. A., Reid, G. S. 2016; 30 (10): 2116-2119

    View details for DOI 10.1038/leu.2016.152

    View details for Web of Science ID 000385801500027

    View details for PubMedID 27220664

    View details for PubMedCentralID PMC5053846

  • Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state JOURNAL OF LEUKOCYTE BIOLOGY Kozicky, L. K., Zhao, Z. Y., Menzies, S. C., Fidanza, M., Reid, G. S., Wilhelmsen, K., Hellman, J., Hotte, N., Madsen, K. L., Sly, L. M. 2015; 98 (6): 983-994

    Abstract

    Intravenous Ig is used to treat autoimmune or autoinflammatory disorders, but the mechanism by which it exerts its immunosuppressive activity is not understood completely. To examine the impact of intravenous Ig on macrophages, we compared cytokine production by LPS-activated macrophages in the presence and absence of intravenous Ig. Intravenous Ig treatment induced robust production of IL-10 in response to LPS, relative to LPS stimulation alone, and reduced production of proinflammatory cytokines. This anti-inflammatory, intravenous Ig-induced activation was sustained for 24 h but could only be induced if intravenous Ig were provided within 1 h of LPS stimulation. Intravenous Ig activation led to enhanced and prolonged activation of MAPKs, Erk1/2, p38, and Erk5, and inhibition of each reduced intravenous Ig-induced IL-10 production and suppression of IL-12/23p40. IL-10 production occurred rapidly in response to intravenous Ig + LPS and was sufficient to reduce proinflammatory IL-12/23p40 production in response to LPS. IL-10 induction and reduced IL-12/23p40 production were transcriptionally regulated. IL-10 played a direct role in reducing proinflammatory cytokine production by macrophages treated with intravenous Ig + LPS, as macrophages from mice deficient in the IL-10R β chain or in IL-10 were compromised in their ability to reduce proinflammatory cytokine production. Finally, intraperitoneal injection of intravenous Ig or intravenous Ig + LPS into mice activated macrophages to produce high levels of IL-10 during subsequent or concurrent LPS challenge, respectively. These findings identify IL-10 as a key anti-inflammatory mediator produced by intravenous Ig-treated macrophages and provide insight into a novel mechanism by which intravenous Ig may dampen down inflammatory responses in patients with autoimmune or autoinflammatory diseases.

    View details for DOI 10.1189/jlb.3VMA0315-078R

    View details for Web of Science ID 000364912000014

    View details for PubMedID 26216934